Compounded vs. FDA-Approved GLP-1s: What Your Telehealth Provider Isn't Telling You

The distinction between compounded and FDA-approved GLP-1 medications is the single most important thing the telehealth industry has failed to communicate clearly. It's also the exact issue at the center of every FDA warning letter issued in 2026.

This isn't about whether compounded medications are inherently dangerous. It's about understanding exactly what you're getting — because your telehealth provider may not be making that clear.

FDA-Approved: What That Actually Means

When a drug is FDA-approved, it has gone through years of clinical trials involving thousands of patients, demonstrating specific levels of safety and efficacy. The manufacturing facility is inspected. Every batch is tested. The labeling is reviewed. Adverse events are tracked through post-market surveillance.

The current FDA-approved GLP-1 medications for weight loss include:

• Wegovy (semaglutide injection) — by Novo Nordisk. Also now available as an oral pill (approved December 2025).
• Zepbound (tirzepatide injection) — by Eli Lilly. Dual GIP/GLP-1 agonist.
• Foundayo (orforglipron) — by Eli Lilly. Oral pill approved April 1, 2026. Non-peptide GLP-1 agonist. Can be taken any time of day without food or water restrictions. Self-pay from $149/month, or as low as $25/month with a savings card.

Compounded: What That Actually Means

Compounded GLP-1 medications contain the same active pharmaceutical ingredient (API) — semaglutide or tirzepatide — but they are prepared by compounding pharmacies rather than the brand-name manufacturer. They have not been reviewed by the FDA for safety, efficacy, or quality. They are not generics.

There are two types of compounding pharmacies:

503A Pharmacies

Traditional compounding pharmacies that prepare patient-specific prescriptions. Each prescription is for an individual patient based on a prescriber's order. These pharmacies are regulated primarily by state boards of pharmacy.

503B Outsourcing Facilities

Larger-scale operations registered with the FDA that can compound without individual prescriptions. Subject to FDA inspection and current Good Manufacturing Practice (cGMP) requirements. This is the pathway that enabled mass-scale telehealth GLP-1 distribution — and it's the pathway the FDA is now working to close.

The Safety Data Gap

As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect doses from multidose vials — some requiring hospitalization.

This doesn't mean compounded GLP-1s are inherently dangerous. But it does mean they carry risks that FDA-approved versions have been specifically designed to minimize — pre-filled pens with fixed doses, for example, versus multidose vials that require manual drawing and measurement.

The Cost Reality

Cost is the primary reason patients choose compounded GLP-1s. With only 34% of employer plans covering GLP-1 medications and brand-name pricing exceeding $1,000 per month without insurance, compounded alternatives at $99–$300 per month fill a genuine access gap. That gap is why the market exists, and why the FDA's position — that affordability does not constitute "clinical need" — is both legally accurate and emotionally unsatisfying for patients.

Your Options Today

If You Want FDA-Approved

If You Want Compounded — With Transparency